argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Founded in 2008, we engineer life-changing immunology solutions through our antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate discovery. Our flagship product, VYVGART (efgartigimod alfa), is a first-in-class neonatal Fc receptor blocker approved for the treatment of generalized myasthenia gravis, with potential to treat patients across dozens of severe autoimmune conditions.
The name argenx originates from the ancient myth of the Argonauts - one of the first stories recognizing the power of the team over individual heroes. This philosophy of co-creation drives everything we do. We believe the resilience and hope of patients gives us purpose, empowering us to work with urgency because we know they are waiting. Our cultural pillars - Innovation, Co-creation, Excellence, Humility, and Empowerment - guide our business relationships and collaborations both within and beyond our walls as we strive to achieve the unthinkable together.